Keybank National Association OH cut its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 3.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,572 shares of the pharmaceutical company’s stock after selling 3,843 shares during the period. Keybank National Association OH’s holdings in GlaxoSmithKline PLC were worth $4,164,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Bronfman E.L. Rothschild L.P. raised its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares during the period. Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares during the period. Heritage Trust Co purchased a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $123,000. Finally, Westwood Holdings Group Inc. raised its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares during the period. Institutional investors own 9.28% of the company’s stock.

Shares of GlaxoSmithKline PLC (GSK) opened at 39.74 on Thursday. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.53. The company has a market cap of $97.12 billion, a price-to-earnings ratio of 39.50 and a beta of 1.03. The company’s 50-day moving average price is $40.70 and its 200 day moving average price is $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 annualized dividend and a dividend yield of 4.94%. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

COPYRIGHT VIOLATION NOTICE: “Keybank National Association OH Reduces Position in GlaxoSmithKline PLC (GSK)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/31/keybank-national-association-oh-reduces-position-in-glaxosmithkline-plc-gsk.html.

GSK has been the topic of a number of research reports. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Tuesday, July 18th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.